Uveitic glaucoma is a range of disorders that results in optic nerve damage from elevated intraocular pressure secondary to intraocular inflammation. As compared to primary open angle glaucoma, uveitic glaucoma is associated with a more aggressive disease course caused by very high intraocular pressure levels that wax and wane. Diagnosis is often based on clinical presentation, disease course, and associated systemic manifestations. Diagnostic imaging plays an important role in both diagnosis and management. While the mechanisms of uveitic glaucoma vary, treatment requires strict control of the inflammation and may involve additional intraocular pressure lowering techniques. Management often dictates an interdisciplinary approach as systemic association and treatment is common. When topical management does not slow the progression of optic nerve damage and vision loss, surgical intervention is required. A significant portion of patients with uveitic glaucoma will eventually require surgical intervention and the appropriate referrals should be made. By nature, success rates of surgical intervention in uveitic glaucoma patients are lower than noninflammatory causes of elevated intraocular pressure and glaucomatous damage. Chronic inflammation, multiple mechanisms, systemic associations, and unpredictable response to treatment make uveitic glaucoma challenging to manage. This review will discuss the pathophysiology, diagnosis, and management of uveitic glaucoma to provide a guide for eye-care providers. 
cause significant visual impairment. Chronic inflammation can lead to posterior synechiae, cataracts, band keratopathy, macular edema and glaucoma. Uveitic glaucoma (UG) is the most visually devastating complication of anterior uveitis. Glaucoma has been reported to affect between nine and 20 per cent of anterior uveitis patients, with varying incidences based on aetiology and population. 1 Intraocular pressure (IOP) elevation associated with anterior uveitis can be caused by an increased resistance to outflow or an IOP response to corticosteroid treatment. 2 Elevated IOP, defined by a measurement above 21-24 mmHg, is significantly more common in patients with chronic inflammation than those with acute inflammation. The balance between treating inflammation and IOP is delicate, providing clinicians with a complex therapeutic challenge. As compared to primary open angle glaucoma, patients with UG have higher IOP and varying responses to IOP lowering pharmaceuticals. 3 Fortunately, medical treatment successfully manages IOP in most uveitic patients. About 30 per cent of patients will require surgical intervention due to insufficient IOP control while on maximum medical therapy. 4 However, surgery is commonly complicated by improper wound healing or failure to maintain IOP. 4 The most common aetiology of anterior uveitis is 'idiopathic', making up 38-70 per cent of all anterior uveitis cases. 1 Other cases are commonly secondary to, or exacerbated by, various ocular and systemic pathologies, including infection, autoimmune response and injury. A successful clinical course occurs when inflammation is strictly controlled, IOP is aggressively lowered and systemic comorbidities are treated. This review intends to provide a clinical guide to optometrists who manage UG, specifically reviewing aetiology, pathophysiology, diagnostic techniques, and management.
mechanisms are secondary to increased resistance to outflow or a corticosteroid response. Acute inflammation will initially decrease IOP by aqueous hyposecretion from inflamed ciliary body and increased uveoscleral outflow. 5 With prolonged inflammation, an imbalance between aqueous production and outflow leads to high IOP levels. 3 Trabecular meshwork obstruction is the most common cause of IOP elevation in UG, created by disruption of the blood aqueous barrier secondary to ocular inflammation. 2 Additional resistance to outflow is a result of mechanical obstruction or direct inflammation of the trabecular meshwork. Both normal serum and inflammatory components -such as cells, proteins, debris, fibrin, and/or precipitates -are captured and suspended in the aqueous, increasing viscosity. Thickening of the aqueous along with physical narrowing of the trabecular meshwork from trabecular lamellae and endothelial cell edema can lead to obstructed outflow. 6 Inflammatory cytokines can further exacerbate disruption of the blood aqueous barrier and can increase the likelihood of neovascularisation of the angle. Ultimately, chronic inflammation can result in scarring or collapse of the trabecular meshwork and/or Schlemm's canal with permanent damage. 7 Corticosteroids are the treatment of choice for anterior uveitis. In many situations, corticosteroid treatment is sufficient to both reduce inflammation and lower the IOP. Unfortunately, one-third of healthy patients will have corticosteroid-induced IOP elevation. 8 Risk factors for steroid-induced IOP elevation are listed in Table 1 . It has been hypothesised that corticosteroids increase resistance to outflow through several mechanisms, all of which maintain an open-angle. In the nucleus of normal trabecular meshwork cells are two glucocorticoid receptors: alpha-receptor and betareceptor. The alpha-receptor works to produce extracellular matrix, while the betareceptor inhibits alpha-receptor activity. 8 12 In total, about 10 per cent of patients with uveitis will suffer from reduced vision due to glaucoma, cystoid macular oedema, or cataracts. 7 Whether IOP elevation is caused by inflammation or a response to corticosteroid treatment, significant vision loss can occur. As previously mentioned, about 20 per cent of patients with chronic uveitis will develop glaucoma. 12 The incidence of UG varies among patients with different ethnicities, ages, and regions, determined by aetiology. 7 There is no age, sex, or racial predilection for UG. 4 Studies from the 1960s suggest UG most often affects patients with median age between 20 and 50 years. 7 A more recent report by Abdulaal et al. 13 showed an increase in cases of uveitis in the elderly population, defined as age 60 and older. About 5-10 per cent of UG cases occur in children under the age of 16. 14 Children with chronic uveitis related to juvenile idiopathic arthritis develop glaucoma in 10-35 per cent of cases. 12 High rates of glaucoma are reported in uveitis associated with infectious disease, systemic disease, and other disorders as described in Table 2 .
Herpetic keratouveitis
Glaucoma is the most common complication in patients with herpetic uveitis. 15 Elevated IOP is associated most often with herpes simplex or varicella zoster, and the mean duration of elevation is two months. 16 The ocular hypertensive episodes can be attributed to primary trabeculitis, along with increase in aqueous viscosity and obstruction of the trabecular meshwork by inflammatory cells and debris.
The viral infection may manifest as conjunctivitis, keratitis, or uveitis, but often presents as a keratouveitis. 15 Forms of keratouveitis include keratic precipitates in a circular pattern with corneal oedema centrally, or diffuse and linear keratic precipitates without significant corneal oedema. 15 Other signs of infectious aetiology are diffuse or sectoral iris atrophy, fibrin, and posterior synechiae. 7 Posterior synechiae are less common in viral infections than other forms of uveitis. 7 Most herpetic uveitis cases can be clinically diagnosed. Serology is not necessary for diagnosis; however, it may be useful in ruling out herpes exposure. A significantly more invasive diagnostic method uses a polymerase chain reaction of an aqueous sample. This option is not currently a recommended clinical procedure as the risk of endophthalmitis outweighs the potential benefit of diagnosis; it is primarily used for research purposes. 16 
Syphilis
A small percentage of patients with syphilis will develop glaucomatous damage from uveitis, with interstitial keratitis having the highest association of developing UG. About 15 per cent of patients with syphilis will develop interstitial keratitis and 20 per cent of patients with interstitial keratitis will develop UG. 2 Glaucomatous damage appears late in the disease course, often without active inflammation.
Gonioscopy reveals open or closed angles and trabecular meshwork with varying amounts of peripheral anterior synechiae or hyaline membranes. 2 Mechanical blockage often does not correlate with levels of IOP elevation. 2 The IOP tends to respond poorly to topical treatment and may require surgical intervention. 2 Syphilis should be ruled out in all patients with granulomatous uveitis because it is curable, and accurate diagnosis with appropriate treatment can prevent disease progression.
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis is an autoimmune disease that typically affects children under the age of 16 years. It is the most common cause of uveitis in children. 17 There are seven sub-types, each with different risks for glaucoma. The lowest risk occurs with systemic juvenile arthritis, classified as stiffness and pain of all joints and paired with intermittent rash, fever, and internal organ involvement. The oligoarticular sub-type holds the highest risk for uveitis development at about 30 per cent. 18 It affects four or fewer joints, often the knee, and less frequently, the ankle or wrist. Symptoms include joint pain, stiffness, or swelling. It affects males more than females by a five-to-one ratio. Polyarticular arthritis involves more than four joints in the first six months of diagnosis. Further sub-typing of oligoarticular and polyarticular arthritis includes anti-nuclear antibody testing. Antinuclear antibody positivity increases the risk of ocular complications. Systemic and oligoarticular types are 10 per cent and 75 per cent anti-nuclear antibody positive, respectively. 18 Patients typically develop arthritis between ages three and six. The uveitis is bilateral, nongranulomatous, asymptomatic, and anterior. In about 5-6 per cent of cases, uveitis is the presenting sign. 18 Those with persistent low-grade uveitis are at the greatest risk of developing glaucoma. About onethird of patients will develop secondary ocular complications, such as posterior synechiae, cataract, band keratopathy, or macular edema. 18 Due to associated sight-threatening conditions and the asymptomatic nature of the disease, patients are monitored as described in Table 3 . 17 Although topical therapeutic treatment is initially effective, surgical intervention may be required in up to 65 per cent of cases. 19 
Fuch's heterochromic uveitis
Fuch's heterochromic uveitis was first described in 1906 as a triad of anterior uveitis, heterochromia, and cataract. 20 It is typically considered a benign condition. Typical onset occurs between ages 20 and 40 and equally affects men and women. 20 The inflammation in the anterior chamber is a result of the breakdown of the iris stroma, leading to an idiopathic, chronic, low-grade uveitis, without synechiae, with diffuse, small stellate keratic precipitates. Other findings include iris atrophy with patchy or moth-eaten appearance on transillumination, secondary to a loss of pigment epithelium. 20 Rarely, posterior synechiae form.
About 87-90 per cent of cases are unilateral, affecting the hypochromatic eye. 20 About 13 per cent are bilateral and challenging to diagnose without hallmark heterochromia. 21 Underdiagnoses occurs due to its asymptomatic and chronic nature. Often treatment of the inflammation is not required, specifically if iridocyclitis is recurrent and minimally symptomatic. 21 The patient may present with mild complaints of blur or light sensitivity, although they can be asymptomatic. Long-term management with corticosteroids may only exacerbate the Given age at onset is less than seven years and no history of iridocyclitis Oligoarthritis or polyarticular Systemic ANA positivity ANA negativity 3-4 months Six months 12 months Anti-nuclear antibody (ANA) positivity increases the frequency of follow ups. 17 With known history of uveitis, patients are monitored at the discretion of the managing clinician. A preliminary study by Shen et al. 27 measured systemic brachial artery endothelial dysfunction with ultrasonography in patients with Posner-Schlossman syndrome. The authors confirmed impaired vascular endothelial function and recommended blood work along with brachial artery ultrasonography. This is not currently a standard of care and further testing would be indicated to determine sensitivity and specificity. In the same study, patients were typed for human leukocyte antigen (HLA)-A and -B autoimmune reactivity. A statistically significant number of patients were positive for HLA-Bw54. Like HLA-B27-related uveitis, some systemic management including nonsteroidal anti-inflammatory drugs, systemic corticosteroids, disease-modifying antirheumatic drugs, or tumor necrosis factor inhibitors, may be required for improved control of the recurrent uveitis. 27 Infection with Helicobacter pylori, herpes simplex or cytomegalovirus, and various forms of allergies have been suggested as aetiologies of Posner-Schlossman syndrome. In a case series of 32 patients by Shen et al., 27 an association between the presence of anti-H. pylori serum immunoglobulin G and Posner-Schlossman syndrome was noted. The authors suggested that there may be a cross-reactivity or antigenicity between the anterior uvea or trabecular meshwork and the intestinal mucosa.
In two studies, about 50 per cent of eyes with presumed Posner-Schlossman syndrome were cytomegalovirus-positive with polymerase chain reaction analysis of aqueous. 28, 29 An additional ocular finding in cytomegalovirus-positive patients was significant endothelial cell loss. 29 Patients were treated with intravitreal antivirals targeted toward cytomegalovirus with success. 22 It is unclear whether resolution was the natural course of the disease or if it was secondary to antiviral treatment. 29 No recommendations have been made for the clinical application of intravitreal antivirals at this time. 
Vogt-Koyanagi-Harada syndrome

Diagnosis
In patients with recurrent or chronic uveitis, an underlying ocular or systemic cause should be investigated. The history and clinical examination will dictate the work up which may include complete blood count, herpetic or syphilis serology, HLA typing, angiotensin converting enzyme and chest Xray. 3 Additional blood work may include antinuclear antibody, enzyme-linked immunosorbent assay, erythrocyte sedimentation rate, purified protein derivative, venereal disease research laboratory, and rapid plasma reagin test. Directed history should focus on infections, arthritis, skin lesions, and nonspecific cough. Diagnosing glaucomatous changes during episodes of inflammation can present a clinical challenge. Gonioscopy should be performed for baseline information on these patients, especially when the IOP is elevated. 3 The architecture of the trabecular meshwork should be evaluated to help determine the aetiology, as IOP tends to be very high in UG. 3 While assessing the angle, the density of pigmentation, iris approach, and presence or absence of nodules should be noted. If the cornea cannot be adequately cleared for gonioscopy, ultrasound biomicroscopy or optical coherence tomography should be performed. As noted previously, oedema of the ciliary body can result in appositional angle-closure and should be assessed with ultrasound biomicroscopy. 3 Optical coherence tomography imaging, specifically imaging of the retinal nerve fibre layer, has become standard documentation for glaucoma. This applies to UG with the understanding that inflammation can influence the results. In a study by Moore et al. 30 patients with active uveitis without glaucoma have significantly thickened retinal nerve fibre layer compared to healthy patients. This is due to the breakdown of the blood-retinal barrier, increased production of prostaglandins, inflammatory cytokines, and vascular permeability. The authors also noted that patients had thicker than expected retinal nerve fibre layer, both during active and quiescent periods, including advanced or end-stage UG defined by visual field testing. 30 Eyes with improving uveitis may demonstrate additional retinal nerve fibre layer thinning and cupping despite good IOP control due to the resolution of retinal oedema. 30 In general, statistically normal thickness in UG patients should be cautiously interpreted. For the most useful information, screening for glaucomatous damage should be performed during quiescent periods.
Treatment and management
Management of UG may appropriately involve medical and surgical treatment. As per the Ocular Immunology and Uveitis Foundation, the preferred practice advocated for uveitis is aimed at a cure, with the first stage being a corticosteroid-free remission. 31 Appropriate diagnosis is imperative for successful treatment and management for both curable cases and chronic, idiopathic cases.
Since uveitis is a multisystem disorder, a multidisciplinary approach is often required for UG. Simultaneous treatment of uveitis and IOP elevation complicates clinical decision-making. 8 Aggressive inflammation control provides the best clinical course for uveitis patients. Short-term elevations in IOP may occur both with inflammation and corticosteroid response, but increased disease duration with mild iridocyclitis holds the highest risk for glaucoma development. 15 Undertreating inflammation to avoid a corticosteroid-induced IOP elevation is a disservice to the patient, as the adverse effects of chronic inflammation can result in more undesirable outcomes as compared to those of short-term IOP elevation. Corticosteroids are the preferred drug used to treat uveitis. 15 It is recommended to initiate treatment with a deep-penetrating topical corticosteroid such as prednisolone acetate, difluprednate, or dexamethasone. Periocular or systemic treatment may be required. 3 Non-steroidal anti-inflammatory drugs are not used to treat UG. 23 In cases of corticosteroid-induced IOP response, steroids with the least propensity to raise IOP, such as loteprednol etabonate, are used. Often these steroids are less potent and should only be substituted when the uveitis is under adequate control or if additional non-steroidal therapeutic agents are being considered.
Oral immunosuppression therapy may be initiated/co-managed with a uveitis specialist or rheumatologist. IOP lowering therapies may include beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogues, and alpha-2 agonists. 3 Cycloplegic agents, such as cyclopentolate, homatropine, or atropine, should be used in combination with anti-inflammatory treatment. Cycloplegic agents provide pain relief by immobilising the iris, preventing adhesion of iris to anterior lens capsule, and stabilising the bloodaqueous barrier, all reducing protein and inflammatory component leakage. 14 
IOP lowering therapy
Topical beta-blockers are considered firstline agents to decrease IOP in patients with UG, assuming no systemic contraindications. 3 Relative contraindications include hypotension, cerebrovascular insufficiency, chronic obstructive pulmonary disease, asthma, emphysema, bradycardia, and congestive heart failure. 3 Carbonic anhydrase inhibitors are an effective agent if betablockers cannot be used. Acetazolamide is used to manage acute IOP elevation and useful before filtering surgeries. Maximum medical management should include oral carbonic anhydrase inhibitors. Recent data suggest that prostaglandin analogues can be considered as first-line agents. 3 Reported adverse effects created controversy over any use of prostaglandin analogues with UG, let alone first-line treatment. Exacerbation of inflammation, bloodaqueous barrier disruption, and cystoid macular oedema due to prostaglandin analogue use has been reported. There is a proven increased risk of reactivation of herpes simplex keratitis. 32 In a study by Markomichelakis et al., 32 the efficacy and safety of latanoprost in 58 patients with UG was compared to a fixed combination of brimonidine and timolol. The authors concluded that latanoprost was a safe and effective alternative for treating IOP in UG patients, especially during quiescent periods. 32 No difference was found in the recurrences of inflammation or cystoid macular oedema. Another study by Taylor et al. 33 determined that the use of prostaglandin analogues does not induce additional conjunctival inflammation. This is important because it has previously been postulated that prostaglandin analogues and chronic conjunctival inflammation had a negative effect on future filtering surgeries. Treatment may start with a topical prostaglandin analogue. If additional treatment is required, a betablocker, carbonic anhydrase inhibitors, or an alpha-2 agonist may be added. If maximum topical therapy is not sufficient, oral carbonic anhydrase inhibitors 250-1,000 mg should be considered. 31 Alpha-2 agonists are considered a useful second-line therapy for IOP lowering in UG. Cases of granulomatous anterior uveitis have been described after long-term use and usually after an allergic reaction. 34 Discontinuation should resolve the inflammation. It is worth noting that an anterior uveitis reactivation may be associated with brimonidine or apraclonidine use in patients with UG. Cholinergic agonists are generally contraindicated in the treatment of UG. Reports of an exacerbation of inflammation via the bloodaqueous barrier breakdown have been noted. 35 Miotics have been known to promote posterior synechiae and are not used.
Surgical intervention
If maximum medical management fails to control glaucomatous damage or IOP, surgical intervention may be required. Interventions include laser therapy, trabeculectomy, drainage devices, minimally invasive glaucoma surgery or cycloablation. 3 Strict control of pre-and post-operative inflammation is imperative for surgical success.
Laser intervention includes peripheral iridotomy and selective laser trabeculoplasty with Nd:YAG laser. 36 In eyes with pupillary block from posterior synechiae or fibrin formation, peripheral iridotomies may be effective in reducing pressure. Often more than one iridotomy is required due to improper healing and excessive fibrin formation. Repeat iridotomies are often required in highly pigmented irides. 36 Argon laser trabeculoplasty is not currently recommended for UG. There is concern about inflammation exacerbation, permanent damage of the trabecular meshwork, and failure to control IOP. 3 Selective laser trabeculoplasty produces less inflammation, has improved IOP lowering effects, and does not alter the structural integrity of the trabecular meshwork. This procedure is an effective alternative to increasing medication or invasive procedures due to its cost-effectiveness, absence of major adverse effects, and simplicity. 38 It is recommended for eyes with mild to moderate UG with an IOP between 20 and 40 mmHg. 37 Traditionally, trabeculectomy is the procedure of choice for surgical intervention. Success rates of 75 per cent have been reported while treating UG. 38 Most recently, a retrospective review by Bettis et al. 38 compared the success rates of trabeculectomy and Ahmed valve implantation in UG patients. The authors concluded that both showed similar success rates of mid-term IOP control and over a three-year period. The Ahmed valve shows a significantly increased rate of success in year one, prolonged duration before failure and a nonsignificant trend toward improved overall success at years two and three. Theoretical benefits of the Ahmed valve were prevention of over-filtration and staged surgical approach to reduce multiple eye manipulations. 38 Goniotomy has been recommended for glaucoma associated with childhood uveitis. Surgical success rates were around 55 per cent. 17 Better outcomes were seen in phakic eyes without peripheral anterior synechiae, age younger than 10, and surgically naïve eyes. It is a low-risk and effective procedure. It is considered the procedure of choice in childhood UG, despite 50 per cent of patients requiring continued post-surgical glaucoma treatment. 17 Currently, few surgical intervention options have undergone prospective, randomised studies. Data have been collected and recommendations have been made for minimally invasive glaucoma surgery, trabectome surgery, and canaloplasty. Each have proven to be attractive alternatives for treating UG and have shown success within the retrospective and case studies. 3 Larger well-designed studies are needed to confirm those conclusions and to determine the safety and efficacy of those procedures.
Conclusion
Uveitis affects over two million people worldwide. There is no age, sex, or race predilection for UG. 
